Interpace Biosciences Overview
Valuation check: IDXG's ROE is 105.18%, above the sector sector average of -5.68%.
Get informed when a big investor buys or sells
+ Follow105.18%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for IDXG is 105.18%. That is above the sector sector average of -5.68%. Investors often review this figure alongside Interpace Biosciences's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, IDXG currently prints 105.18% for ROE, while the sector average sits near -5.68%. That is roughly 1950.7% above the sector mean. Large gaps often invite a closer look at Interpace Biosciences's growth, margins, and balance sheet.
Return on Equity shows how effectively Interpace Biosciences converts resources into returns. At 105.18%, IDXG may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting IDXG's ROE (105.18%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
